Company intelligence / Profile preview

Orphagen Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Orphagen’s most advanced candidates include novel nuclear receptor antagonists, targeting indications in oncology and immunology, with OR-449 and OR-812 in preclinical development. OR-812 (RARα antagonist) demonstrated promising preclinical efficacy and safety for inflammatory bowel disease, supported by NIH funding.

Therapeutic areas: OncologyImmunologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Mid-size pharma for RORγ programOther undisclosed collaborators

Beyond the preview

Go deeper on Orphagen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphagen Therapeutics.

Explore the full profile